Abstract: Procedures for inhibiting hormone receptor activation include administering to a subject in need of hormone receptor inhibition a compound having a chemical structure of a molecule that, when docked in the PPIase pocket, could disrupt proline-rich loop conformation and interactions. Procedures for treating prostate cancer or breast cancer include administering to a subject having prostate cancer or breast cancer a compound having a chemical structure of a molecule that, when docked in the PPIase pocket, could disrupt proline-rich loop conformation and interactions.

Abstract: Procedures for inhibiting hormone receptor activation include administering to a subject in need of hormone receptor inhibition a compound having a chemical structure of a molecule that, when docked in the PPIase pocket, could disrupt proline-rich loop conformation and interactions. Procedures for treating prostate cancer or breast cancer include administering to a subject having prostate cancer or breast cancer a compound having a chemical structure of a molecule that, when docked in the PPIase pocket, could disrupt proline-rich loop conformation and interactions.

Abstract: Procedures for inhibiting hormone receptor activation include administering to a subject in need of hormone receptor inhibition a compound having a chemical structure of a molecule that, when docked in the PPIase pocket, could disrupt proline-rich loop conformation and interactions. Procedures for treating prostate cancer or breast cancer include administering to a subject having prostate cancer or breast cancer a compound having a chemical structure of a molecule that, when docked in the PPIase pocket, could disrupt proline-rich loop conformation and interactions.

Abstract: Embodiments of the current invention include methods and compositions for regulating the activity of hormone receptors.

Abstract: Embodiments of the current invention include methods and compositions for regulating the activity of hormone receptors.

Abstract: Embodiments of the current invention include methods and compositions for regulating the activity of hormone receptors.

Abstract: Certain embodiments are directed to a GMC1 co-solvent formulation. The GMC1 co-solvent formulation described herein can be used for the treatment of prostate cancer, benign prostatic hypertrophy, and other hormone-related conditions involving androgen, glucocorticoid, and progesterone receptors.

Abstract: Certain embodiments are directed to a GMC1 co-solvent formulation. The GMC1 co-solvent formulation described herein can be used for the treatment of prostate cancer, benign prostatic hypertrophy, and other hormone-related conditions involving androgen, glucocorticoid, and progesterone receptors.

Abstract: Embodiments of the current invention include methods and compositions for regulating the activity of hormone receptors.

Abstract: A display device comprising a plurality of parallelepipeds (4) arranged in a stack, each parallelepiped having a resilient means (11) for urging it from a closed position, in which it lies generally flat, to a fully opened position, the structure being foldable from a first position as which the stack of parallelepipeds are fully open to a second position at which they are fully loaded.

Abstract: A self-erecting display device is disclosed, comprising a display panel supported by a collapsible structure secured to its reverse side, the collapsible structure comprising an elongate back panel and a pair of side panels integrally hinged to the respective longitudinal edges of the back panel, the side panels provided with means for receiving part of a resilient means whereby at least one resilient means is applied between respective parts of the side panels so as to draw the side panels towards each other when the display structure is erected, and at least one spacer element mounted by means of the resilient means and adapted to lie against the elongate back panel when the structure is un-erected and to be spaced away from the back panel, supported by the resilient means and abutting the side panels when the device is erected.